Details

Autor(en) / Beteiligte

• Howard, Jr, James F
• Bresch, Saskia
• Farmakidis, Constantine
• Freimer, Miriam
• Genge, Angela
• Hewamadduma, Channa
• Hinton, John
• Hussain, Yessar
• Juntas-Morales, Raul
• Kaminski, Henry J
• Maniaol, Angelina
• Mantegazza, Renato
• Masuda, Masayuki
• Nowak, Richard J
• Sivakumar, Kumaraswamy
• Śmiłowski, Marek
• Utsugisawa, Kimiaki
• Vu, Tuan
• Weiss, Michael D
• Zajda, Małgorzata
• Bloemers, Jos
• Boroojerdi, Babak
• Brock, Melissa
• de la Borderie, Guillemette
• Duda, Petra W
• Vanderkelen, Mark
• Leite, M Isabel

Titel

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Ist Teil von

• Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241243186-17562864241243186

Ort / Verlag

England: SAGE Publications

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments. To evaluate the long-term safety, tolerability, and efficacy of zilucoplan in a mild-to-severe, acetylcholine receptor autoantibody-positive (AChR+) gMG population. Ongoing, multicenter, phase III open-label extension (OLE) study. Eligible patients had completed a qualifying randomized, placebo-controlled phase II or phase III zilucoplan study and received daily, self-administered subcutaneous 0.3 mg/kg zilucoplan. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Secondary efficacy endpoints included change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score. In total, 200 patients enrolled. At the cut-off date (8 September 2022), median (range) exposure to zilucoplan in RAISE-XT was 1.2 (0.11-4.45) years. Mean age at OLE baseline was 53.3 years. A total of 188 (94%) patients experienced a TEAE, with the most common being MG worsening (  = 52, 26%) and COVID-19 (  = 49, 25%). In patients who received zilucoplan 0.3 mg/kg in the parent study, further improvements in MG-ADL score continued through to Week 24 (least squares mean change [95% confidence interval] from double-blind baseline -6.06 [-7.09, -5.03]) and were sustained through to Week 60 (-6.04 [-7.21, -4.87]). In patients who switched from placebo in the parent study, rapid improvements in MG-ADL score were observed at the first week after switching to zilucoplan; further improvements were observed at Week 24, 12 weeks after switching (-6.46 [-8.19, -4.72]), and were sustained through to Week 60 (-6.51 [-8.37, -4.65]). Consistent results were observed in other efficacy endpoints. Zilucoplan demonstrated a favorable long-term safety profile, good tolerability, and sustained efficacy through to Week 60 with consistent benefits in a broad AChR+ gMG population. Additional long-term data will be available in future analyses. ClinicalTrials.gov identifier: NCT04225871 (https://clinicaltrials.gov/ct2/show/NCT04225871).